TNFSF10 and neoplasm: To investigate whether miR-106b inhibitors increased the anti-tumor effect of TRAIL in vivo, we established the in vivo model of HCC by using lentivirus transfected HepG2 cells (LT-control transfected HepG2 or LT-anti-miR-106b transfected HepG2).